Oruka Therapeutics (ORKA) Cash from Investing Activities (2010 - 2026)
Oruka Therapeutics' (ORKA) quarterly Cash from Investing Activities came in at -$14.4 million in Q1 2026, down 133.68% year-on-year from $42.9 million in Q1 2025, and up 34.44% quarter-over-quarter from -$22.0 million in Q4 2025.
Oruka Therapeutics (ORKA) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$14.4 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 133.68% year-over-year to -$14.4 million in Q1 2026; TTM through Mar 2026 was -$154.0 million, a 46.37% increase from a year earlier, with the FY2025 full-year figure at -$96.7 million, up 70.69% from the prior year.
- Cash from Investing Activities grew to -$14.4 million in Q1 2026 per ORKA's latest filing, from -$22.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $42.9 million in Q1 2025 and bottomed at -$330.0 million in Q4 2024.
- The 4-year median for Cash from Investing Activities is -$7.3 million (2024), against an average of -$55.2 million.
- Biggest YoY gain for Cash from Investing Activities was 93.33% in 2025; the steepest drop was 71507.6% in 2025.
- Year by year, Cash from Investing Activities stood at -$2000.0 in 2022, then tumbled by 16497700.0% to -$330.0 million in 2024, then soared by 93.33% to -$22.0 million in 2025, then soared by 34.44% to -$14.4 million in 2026.
- Per Business Quant, the three latest ORKA Cash from Investing Activities figures stand at -$14.4 million (Q1 2026), -$22.0 million (Q4 2025), and -$122.4 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Oruka Therapeutics | 958.00 Mn | 126.85 Mn | - | -14.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.44 Mn |
| Mar 31, 2026 | -14.44 Mn |
| Dec 31, 2025 | -22.02 Mn |
| Dec 31, 2025 | -22.02 Mn |
| Sep 30, 2025 | -122.45 Mn |
| Sep 30, 2025 | -122.45 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Mar 31, 2025 | 42.87 Mn |
| Mar 31, 2025 | 42.87 Mn |
| Dec 31, 2024 | -329.96 Mn |
| Dec 31, 2024 | -329.96 Mn |
| Sep 30, 2024 | -171,000.00 |
| Sep 30, 2024 | -171,000.00 |
| Mar 31, 2022 | -2,000.00 |
| Mar 31, 2022 | -2,000.00 |
| Dec 31, 2021 | -7,000.00 |
| Dec 31, 2021 | -7,000.00 |
| Sep 30, 2021 | -14,000.00 |
| Sep 30, 2021 | -14,000.00 |